Proceedings (Aug 2019)
Targeting Neuronal Transcription Factor BRN2 in Neuroendocrine Tumors
Abstract
No targeted therapies exist against aggressive neuroendocrine tumors; hence, these patients are limited to platinum-based chemotherapy that has not advanced in over three decades. [...]
Keywords